FDA Brief

Warning letters Drugs

FDA warning letter to

www.mysteroidsmarket.com

High riskIssued Jul 17, 2025Posted Jul 29, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Israel-based website mysteroidsmarket.com for selling unapproved and misbranded stimulants and benzodiazepines to U.S. consumers.

What happened

FDA reviewed the website www.mysteroidsmarket.com and found it offered Schedule II stimulants and benzodiazepines for sale to U.S. consumers, including products marketed as Adderall XR, clonazepam and Ativan. FDA said no approved applications were in effect for these products and that prescription drugs were offered without a prescription.

What FDA found

  1. The website offered amphetamine products marketed as “Buy Adderall Xr 30mg” and “ADDERALL XR®” without an FDA-approved application.

    section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]
  2. The website offered clonazepam and lorazepam products without FDA-approved applications.

    section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]
  3. The website sold prescription drugs without requiring a prescription, so the drugs were misbranded.

    section 503(b)(1) and section 301(k) of the FD&C Act [21 U.S.C. §§ 353(b)(1), 331(k)]
  4. The labeling for these prescription drugs did not bear adequate directions for use by a layperson.

    section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]
  5. By offering these drugs to U.S. consumers, the website caused misbranded drugs to be introduced into interstate commerce.

    section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
  6. The drugs are unapproved new drugs because they are not generally recognized as safe and effective for their labeled uses.

    section 201(p) and section 505(a) of the FD&C Act [21 U.S.C. §§ 321(p), 355(a)]

What FDA wants

FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to correct the violations and prevent recurrence.

Who should pay attention

  • online pharmacies and websites selling to U.S. consumers
  • consumers who buy prescription drugs online
  • companies that handle or advertise controlled substances

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk